SAN DIEGO, Jul 27, 2010 (BUSINESS WIRE) --
Illumina, Inc. (NASDAQ:ILMN) today announced the creation of the Illumina Genome Network, a global partnership designed to link researchers interested in conducting large-scale whole human genome sequencing projects with leading institutions that can perform such projects using Illumina sequencing. The Genome Network will provide researchers who do not have access to high-quality, next-generation sequencing technology an economical and dependable way to complete their sequencing projects.
"With the rapidly increasing output of the Illumina HiSeq(TM) 2000, and the commensurate reduction in the price of sequencing genomes, more and more researchers are looking to advance their projects by leveraging this transformational technology," said Christian Henry, Senior Vice President and General Manager, Life Sciences. "By creating the Illumina Genome Network, we believe we can catalyze the development of the market for whole human genome sequencing and help the research community to accelerate the rate of research in human health and population genetics."
The Illumina Genome Network will include leading academic and commercial institutions worldwide that can rapidly process large-scale sequencing projects. Participating institutions must also have completed Illumina's Certified Service Provider (CSPro) certification. Illumina will serve as the channel to connect interested researchers with Network partners that will then perform the sequencing. The Network will focus on offering only whole genome human sequencing services for large scale projects. GMI/Macrogen Inc. and the National Center for Genome Resources (NCGR) have already enrolled as partners in the Network. Illumina is in discussions with a number of other institutions about potentially joining the Network, among them the Broad Institute, BGI, University of Washington Department of Genome Sciences, and deCODE Genetics.
Illumina will begin offering whole human genome sequencing services through the Network immediately.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in launching a new service involving multiple parties and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
+858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Sr. Manager, Public Relations
+858-882-6822
wgrabill@illumina.com
